Status:
COMPLETED
A Study of LY3841136 in Healthy and Overweight Participants
Lead Sponsor:
Eli Lilly and Company
Conditions:
Obesity
Healthy
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
Brief Summary
The main purpose of this study is to evaluate the safety and tolerability of LY3841136 in healthy and overweight participants. Blood tests will be performed to check how much LY3841136 gets into the b...
Eligibility Criteria
Inclusion
- Male participants who agree to use highly effective/effective methods of contraception and female participants not of childbearing potential
- Have had a stable weight for the last 3 months
- Have a body mass index (BMI) in the range of 18.5 to 32 kilogram per square meter (kg/m²), both inclusive (in Part A) or a BMI in the range of 27 to 40 kg/m², both inclusive (in Part B)
Exclusion
- Are women who are lactating
- Have known allergies to related compounds of LY3841136 or any components of the formulation
- Have a history of significant atopy (severe or multiple allergic manifestations), or clinically significant multiple or severe drug allergies, or severe posttreatment hypersensitivity reactions
- Have been diagnosed with Type 1 or Type 2 diabetes mellitus
- Have a history of chronic medical conditions involving the heart, liver, or kidneys
Key Trial Info
Start Date :
March 30 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 25 2024
Estimated Enrollment :
148 Patients enrolled
Trial Details
Trial ID
NCT05295940
Start Date
March 30 2022
End Date
January 25 2024
Last Update
April 1 2024
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Fortrea Clinical Research Unit
Daytona Beach, Florida, United States, 32117
2
Fortrea Clinical Research Unit
Dallas, Texas, United States, 75247
3
Fortrea Clinical Research Unit
Madison, Wisconsin, United States, 53704